Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ozempic (semaglutide)
Fierce Pharma
Novo struggles to appease restless investors with new strategy
CEO Mike Doustdar acknowledged that the company’s leadership “have to convince” investors that “there is a bright future for Novo.”
James Waldron
,
Fraiser Kansteiner
Sep 21, 2026 10:50am
Fierce Pharma
Novo CEO talks embracing change and staying bullish amid rebrand
Sep 17, 2026 8:45am
Fierce Pharma
No more Nordisk as Novo goes it alone amid rebranding push
Sep 14, 2026 6:54am
Novo Nordisk pens GLP-1 implant tech deal with Vivani Medical
Jul 7, 2026 9:07am
Fierce Pharma
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
Jun 11, 2026 7:00am
BrightGene's oral drug sees up to 8% weight loss in early data
Mar 25, 2026 4:04am
